PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17588584-6	2008	At the end of the study, these parameters were significantly lower in the pioglitazone group as compared to the placebo group (MMP-9: 392+/-286 versus 427+/-166 ng/ml; hsCRP: 1.9+/-1.7 versus 3.1+/-2.3 ng/L; MCP-1: 413+/-115 versus 471+/-146 pg/ml; p<0.05, respectively).	Pioglitazone	74-86	C-C motif chemokine ligand 2	Homo sapiens	208-213	
22441004-1	2012	OBJECTIVE: To observe the effects of pioglitazone hydrochloride on urinary sediment podocalyxin and monocyte chemoattractant protein-1 (MCP-1) excretion in patients with type 2 diabetes and to explore its possible renoprotective mechanisms.	Pioglitazone	37-63	C-C motif chemokine ligand 2	Homo sapiens	100-134	
20371128-0	2010	Hydrochloride pioglitazone decreases urinary monocyte chemoattractant protein-1 excretion in type 2 diabetics.	Pioglitazone	14-26	C-C motif chemokine ligand 2	Homo sapiens	45-79	
20371128-1	2010	AIM: To observe the effects of hydrochloride pioglitazone on monocyte chemoattractant protein-1 (MCP-1) excretion in type 2 diabetics and explore its reno-protective mechanism.	Pioglitazone	45-57	C-C motif chemokine ligand 2	Homo sapiens	61-95	
20371128-1	2010	AIM: To observe the effects of hydrochloride pioglitazone on monocyte chemoattractant protein-1 (MCP-1) excretion in type 2 diabetics and explore its reno-protective mechanism.	Pioglitazone	45-57	C-C motif chemokine ligand 2	Homo sapiens	97-102	
20371128-8	2010	CONCLUSIONS: Pioglitazone can decrease urinary albumin and MCP-1 excretion in type 2 diabetics, which may partly contribute to its reno-protection by inhibiting the inflammation reaction in vivo.	Pioglitazone	13-25	C-C motif chemokine ligand 2	Homo sapiens	59-64	
17255125-7	2007	PPAR-gamma"s activation with 15d-PGJ2 or pioglitazone reduced basal and TNF-alpha-stimulated MCP-1 expression at mRNA and protein levels at 24 h under normoxia.	Pioglitazone	41-53	C-C motif chemokine ligand 2	Homo sapiens	93-98	
18584038-7	2008	Pioglitazone and troglitazone demonstrated opposing actions on microglial CCL2 production that were TLR ligand-dependent.	Pioglitazone	0-12	C-C motif chemokine ligand 2	Homo sapiens	74-78	
17255125-8	2007	MCP-1 reduction rates at basal mRNA and protein levels were slightly but significantly lower during hypoxia than normoxia (9 vs 69% and 36 vs 42%, respectively, for 15d-PGJ2, and 0 vs 34% and 12 vs 21%, respectively, for pioglitazone).	Pioglitazone	221-233	C-C motif chemokine ligand 2	Homo sapiens	0-5	
25897968-10	2015	Further, rosiglitazone and pioglitazone treatment reduced serum hsCRP and MCP-1 but had no marked effects on MMP-9, IL-6 and ICAM-1.	Pioglitazone	27-39	C-C motif chemokine ligand 2	Homo sapiens	74-79	
16046295-0	2005	Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone.	Pioglitazone	178-190	C-C motif chemokine ligand 2	Homo sapiens	23-59	
16046295-7	2005	Pioglitazone increased S(I) by 60% and in the same subjects reduced both CD68 and MCP-1 mRNAs by >50%.	Pioglitazone	0-12	C-C motif chemokine ligand 2	Homo sapiens	82-87	
16046295-10	2005	Thus, treatment with pioglitazone reduces expression of CD68 and MCP-1 in adipose tissue, apparently by reducing macrophage numbers, resulting in reduced inflammatory cytokine production and improvement in S(I).	Pioglitazone	21-33	C-C motif chemokine ligand 2	Homo sapiens	65-70	
12411463-6	2002	Pioglitazone did not reduce local expression of MCP-1 but markedly attenuated increased expression of the MCP-1 receptor C-C chemokine receptor 2 (CCR2) in lesional and circulating monocytes.	Pioglitazone	0-12	C-C motif chemokine ligand 2	Homo sapiens	106-111	
28867378-9	2017	Both ROS and PGZ significantly induced the release of adiponectin and inhibited release of MCP-1 from the fat.	Pioglitazone	13-16	C-C motif chemokine ligand 2	Homo sapiens	91-96